JPMorgan Starts Mallinckrodt plc (MNK) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Mallinckrodt plc (MNK) Target Lifted to $77 at Jefferies
March 14, 2014 6:45 AM EDTJefferies analyst Anthony Petrone reiterated a Buy rating and lifted his price target on Mallinckrodt plc (NYSE: MNK) from $66 to $77.
Analyst Anthony Petrone said, "Lack of abuse deterrence in label does not dramatically alter our near-term outlook for the product;... More
Depomed (DEPO) Reports FDA Approval of XARTEMIS XR NDA
March 12, 2014 9:02 AM EDTDepomed, Inc. (Nasdaq: DEPO) announced that the U.S. Food and Drug Administration (FDA) approved Mallinckrodt plc's (NYSE: MNK) New Drug Application (NDA) for XARTEMIS XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII), previously known as MNK-795, for the management of acute pain severe enough to require opioid treatment and in patients for whom alternative... More
